Pulse Biosciences
Pulse Biosciences reported revenue of $0 million in fiscal 2025. Its operating margin was −21,982.6%. Free cash flow was −$54 million. The diluted share count rose 15.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Pulse Biosciences does
Pulse Biosciences is a medical device company. Its technology, called Nano-pulse Stimulation, sends extremely short pulses of electrical energy into tissue to clear or kill targeted cells without heat. The company calls the surgical use of this method nanosecond pulsed-field ablation.
Its main product is the nPulse System, a console plus single-use applicators. The company first sold it for benign skin lesions. Since 2022 it has focused on atrial fibrillation, an irregular heartbeat, and on soft tissue ablation in surgery. The Vybrance Percutaneous Electrode System, a needle electrode, received FDA 510(k) clearance in March 2024. It is being placed at US sites under pilot and early commercial agreements, and a clinical trial on thyroid nodules began in September 2025. Two heart products, a surgical clamp and a catheter, are still in development.
The company has not generated significant revenue. Its revenue depends on one family of products, and it competes with large, established makers of medical devices. As of December 31, 2025, it had 116 employees, most at its facility in Hayward, California.
Its biggest risks, as it describes them
- Never having had significant revenue, and no assurance it will ever be profitable.
- Needing more funding to carry out its business plan.
- Its revenue depends entirely on one family of products and one platform technology.
- Competition from large, well-established makers of medical devices.
- Clinical trials that may fail, and surgeons who may not adopt its technology.
Income statement
Pulse Biosciences lost money in fiscal 2025: a net loss of $73 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 29 | 61 | 44 | 118 | 81 |
| Debt incl. finance leases | — | 66 | 0 | 0 | 0 |
| Net debt (negative means net cash) | — | 5 | −44 | −118 | −81 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.3x | 10.4x | 6.8x | 11.9x | 10.5x |
| Quick ratio | 3.6x | 10.4x | 6.8x | 11.9x | 10.5x |
Cash flow
Projections
Project Pulse Biosciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Pulse Biosciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 2 of 8 | 3 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | −16.09 | −0.19 | −10.11 |
| Accruals ratio | −13.4% | −18.0% | −16.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 3 of 8 | 2 of 8 | 3 of 8 |
Compare
Put Pulse Biosciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pulse Biosciences | FY25 | — | −21,982.6% | −15,553.4% | — | — | 3 | |
| Anteris Technologies Global | FY25 | −29.2% | −4,908.2% | −4,169.2% | — | — | — | Compare |
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | 0 | 1 | 1 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | −50.6% | −100.0% | — | — |
| Gross profit | — | — | — | — | 0 | −0 | −11 | 0 | 0 | −0 |
| Research and development | 6 | 10 | 17 | 25 | 26 | 29 | 21 | 28 | 32 | 45 |
| Operating income | −10 | −26 | −38 | −48 | −50 | −63 | −58 | −44 | −56 | −77 |
| Net income | −10 | −26 | −38 | −47 | −50 | −64 | −58 | −42 | −54 | −73 |
| Diluted EPS (US$) | −0.86 | −1.73 | −2.20 | −2.26 | −2.14 | −2.28 | — | — | — | — |
| Diluted shares (millions) | 11 | 15 | 17 | 21 | 23 | 28 | 34 | 50 | 58 | 67 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −11 | −24 | −34 | −35 | −54 | −47 | −33 | −36 | −54 |
| Capital expenditure | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −8 | −14 | −24 | −35 | −36 | −55 | −47 | −33 | −36 | −54 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 11 | 12 | 11 | 10 | 15 | 5 | 7 | 14 | 22 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 16 | — | 51 | 7 | 20 | 29 | 61 | 44 | 118 | 81 |
| Debt incl. finance leases | — | — | — | — | — | — | 66 | 0 | 0 | 0 |
| Total assets | 26 | 50 | 71 | 42 | 41 | 54 | 78 | 59 | 132 | 94 |
| Total liabilities | 1 | 4 | 4 | 11 | 18 | 19 | 80 | 15 | 18 | 14 |
| Shareholders' equity | 25 | 46 | 66 | 31 | 23 | 36 | −2 | 44 | 115 | 81 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | −38.8% | −1,606.3% | — | — | −54.0% |
| Operating margin | — | — | — | — | — | −4,443.9% | −8,293.9% | — | — | −21,982.6% |
| Net margin | — | — | — | — | — | −4,489.4% | −8,357.9% | — | — | −20,794.6% |
| Free cash flow margin | — | — | — | — | — | −3,845.8% | −6,773.4% | — | — | −15,553.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | −6,824.1% | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −48.9% | −71.7% | −66.8% | −96.8% | −185.9% | −217.3% | −349.9% | −200.5% | −67.3% | −74.5% |
| Return on assets | −46.8% | −67.2% | −62.3% | −83.5% | −119.8% | −133.3% | −88.6% | −61.6% | −55.9% | −64.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |